Long-term survivors and gilteritinib safety beyond 1 year in patients with FLT3-mutated relapsed or refractory acute myeloid leukemia: ADMIRAL trial follow-up

被引：0
|
作者：
Perl, Alexander E. [1 ]
Martinelli, Giovanni [2 ]
Neubauer, Andreas [3 ]
Berman, Ellin [4 ]
Baer, Maria R. [5 ]
Larson, Richard A. [6 ]
Fathi, Amir T. [7 ]
Yokoyama, Hisayuki [8 ]
Hosono, Naoko [9 ]
Hasabou, Nahla [10 ]
Lu, Qiaoyang [10 ]
Tiu, Ramon V. [10 ]
机构：
[1] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA
[2] Ist Sci Romagnolo Studio & Cura Tumori IRST IRCCS, Meldola, Italy
[3] Univ Klinikum Giessen & Marburg GmbH, Marburg, Germany
[4] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[5] Univ Maryland, Greenebaum Comprehens Canc Ctr, Baltimore, MD 21201 USA
[6] Univ Chicago, Chicago, IL 60637 USA
[7] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA 02115 USA
[8] Natl Hosp Org, Sendai Med Ctr, Sendai, Miyagi, Japan
[9] Univ Fukui, Fukui, Japan
[10] Astellas Pharma US Inc, Northbrook, IL USA
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2021年 / 193卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
BSH2021-OR
引用
收藏
页码：3 / 4
页数：2
相关论文
共 50 条
  • [31] A SYSTEMATIC REVIEW OF THE HUMANISTIC BURDEN OF FLT3-MUTATED RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA
    Casamayor, M.
    Gubbels, L.
    Garnham, A.
    Shah, M., V
    VALUE IN HEALTH, 2020, 23 : S29 - S29
  • [32] ESTIMATION OF HEALTH STATE UTILITIES IN FLT3-MUTATED RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA
    Cella, D.
    Qi, C. Z.
    Yang, H.
    Garnham, A.
    Shah, M., V
    VALUE IN HEALTH, 2020, 23 : S77 - S78
  • [33] Gilteritinib Versus Salvage Chemotherapy for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: A Phase 3, Randomized, Multicenter, Open-Label Trial in Asia
    Wang, Jianxiang
    Jiang, Bin
    Li, Jian
    Liu, Ligen
    Du, Xin
    Jiang, Hao
    Hu, Jianda
    Yuan, Menghe
    Sakatani, Taishi
    Kadokura, Takeshi
    Takeuchi, Masato
    Izuka, Shunsuke
    Girshova, Larisa
    Tan, Jerome
    Bondarenko, Sergey N.
    Wong, Lily L. L.
    Khuhapinant, Archrob
    Martynova, Elena
    Hasabou, Nahla
    Tiu, Ramon V.
    BLOOD, 2021, 138
  • [34] Mechanisms of Acquired Resistance to Gilteritinib Therapy in Relapsed and Refractory FLT3 -Mutated Acute Myeloid Leukemia
    McMahon, Christine M.
    Canaani, Jonathan
    Rea, Bryan
    Sargent, Rachel Lynn
    Morrissette, Jennifer J. D.
    Lieberman, David B.
    Watt, Christopher
    Schwartz, Gregory W.
    Faryabi, Robert B.
    Ferng, Timothy T.
    Shah, Neil P.
    Smith, Catherine C.
    Carroll, Martin
    Perl, Alexander E.
    BLOOD, 2017, 130
  • [35] Gilteritinib plus azacitidine and venetoclax for FLT3-ITD mutated relapsed/refractory acute myeloid leukemia
    Chen, Nianci
    Zhou, Yile
    Tong, Hongyan
    Wei, Juying
    Lou, YinJun
    Zhou, De
    Fan, Cuihua
    Huang, Li
    Mao, Liping
    Li, Chenying
    Wang, Huafeng
    Jin, Jie
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [36] Gilteritinib Monotherapy in Relapsed or Refractory Acute Myeloid Leukemia Flt3+in Adult Patients
    Bondarenko, Sergey
    Morozova, Elena
    Smirnova, Anna
    Vlasova, Yuliya
    Ayubova, Bella
    Karyagina, Elena
    Ilyasov, Ridvan
    Zorina, Natalia
    Belyaeva, Svetlana
    Tsvetkov, Nikolai
    Oleynikova, Yulia
    Barkhatov, Ildar
    Gindina, Tatiana
    Moiseev, Ivan
    Kulagin, Alexander
    BONE MARROW TRANSPLANTATION, 2021, 56 (SUPPL 1) : 188 - 188
  • [37] Comparison of Gilteritinib and Salvage Chemotherapy in FLT3-Mutated Acute Myeloid Leukemia on the Number Needed to Treat for Various Clinical Outcomes: A Secondary Analysis of the Admiral Trial
    Pandya, Bhavik J.
    Qi, Cynthia Z.
    Yang, Hongbo
    Garnham, Andy
    Shah, Manasee V.
    Zeidan, Amer M.
    BLOOD, 2020, 136
  • [38] Gilteritinib vs salvage chemotherapy in FLT3-mutated acute myeloid leukemia: number needed to treat for clinical outcomes per a secondary analysis of the ADMIRAL trial
    Zeidan, Amer M.
    Qi, Cynthia Z.
    Yang, Hongbo
    Garnham, Andy
    Shah, Manasee V.
    Pandya, Bhavik J.
    LEUKEMIA & LYMPHOMA, 2022, 63 (03) : 762 - 764
  • [39] Gilteritinib-Based Combination Therapy in Adult Relapsed/Refractory FLT3 Mutated Acute Myeloid Leukemia
    Chen, Nianci
    Pan, Jiajia
    Zhou, Yile
    Mao, Liping
    Lou, Yinjun
    Qian, Jiejing
    Xu, Gaixiang
    Wei, Juying
    Zhou, De
    Shou, Lihong
    Li, Huang
    Yan, Minchao
    Zeng, Hui
    Fan, Cuihua
    Wu, Gongqiang
    Feng, Weiying
    Tong, Hongyan
    Jin, Jie
    Wang, Huafeng
    BLOOD, 2023, 142
  • [40] Relationship between patient-reported outcomes and clinical outcomes in patients with FLT3-mutated relapsed/refractory acute myeloid leukemia: results from the ADMIRAL study
    Cella, D.
    Ritchie, E.
    Fabbiano, F.
    Pigneux, A.
    Kanda, Y.
    Ivanescu, C.
    Pandya, B. J.
    Shah, M. V.
    SWISS MEDICAL WEEKLY, 2020, : 15S - 15S
12345